252 related articles for article (PubMed ID: 31293091)
1. Hürthle cell lesions on thyroid fine needle aspiration cytology: Molecular and histologic correlation.
Schatz-Siemers N; Brandler TC; Oweity T; Sun W; Hernandez A; Levine P
Diagn Cytopathol; 2019 Oct; 47(10):977-985. PubMed ID: 31293091
[TBL] [Abstract][Full Text] [Related]
2. "Copy number alteration" as the sole molecular finding of a Thyroseq test is more commonly seen in Hurthle cell neoplasms.
Kim TH; Rodriguez EF; Lim D; Moatamed NA
Diagn Cytopathol; 2023 Nov; 51(11):705-711. PubMed ID: 37533334
[TBL] [Abstract][Full Text] [Related]
3. The prevalence and surgical outcomes of Hürthle cell lesions in FNAs of the thyroid: A multi-institutional study in 6 Asian countries.
Agarwal S; Bychkov A; Jung CK; Hirokawa M; Lai CR; Hong S; Kwon HJ; Rangdaeng S; Liu Z; Su P; Kakudo K; Jain D
Cancer Cytopathol; 2019 Mar; 127(3):181-191. PubMed ID: 30668897
[TBL] [Abstract][Full Text] [Related]
4. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
5. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
6. Molecular alterations in Hürthle cell neoplasms of thyroid: A fine needle aspiration cytology study with cytology-histology correlation.
Gilani SM; Ross JA; Prasad ML; Hammers L; Cai G; Adeniran AJ
Cancer Cytopathol; 2021 May; 129(5):363-373. PubMed ID: 33045146
[TBL] [Abstract][Full Text] [Related]
7. Malignancy risk for solitary and multiple nodules in Hürthle cell-predominant thyroid fine-needle aspirations: A multi-institutional study.
Wong KS; Jo VY; Lowe AC; Faquin WC; Renshaw AA; Shah AA; Roh MH; Stelow EB; Krane JF
Cancer Cytopathol; 2020 Jan; 128(1):68-75. PubMed ID: 31751003
[TBL] [Abstract][Full Text] [Related]
8. Hürthle cell presence alters the distribution and outcome of categories in the Bethesda system for reporting thyroid cytopathology.
Yazgan A; Balci S; Dincer N; Kiyak G; Tuzun D; Ersoy R; Cakir B; Guler G
Cytopathology; 2014 Jun; 25(3):185-9. PubMed ID: 24024935
[TBL] [Abstract][Full Text] [Related]
9. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
[No Abstract] [Full Text] [Related]
10. Hurthle cells in fine needle aspiration cytology of the thyroid: a potential diagnostic dilemma?
Wong YP; Md Isa N; Md Zin RR; Noor Akmal S
Malays J Pathol; 2015 Apr; 37(1):49-52. PubMed ID: 25890614
[TBL] [Abstract][Full Text] [Related]
11. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
12. Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?
Giorgadze T; Rossi ED; Fadda G; Gupta PK; Livolsi VA; Baloch Z
Diagn Cytopathol; 2004 Nov; 31(5):307-12. PubMed ID: 15468114
[TBL] [Abstract][Full Text] [Related]
13. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
14. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
15. Cytotechnologist Performance for Screening Hürthle Cell Atypia in Indeterminate Thyroid Fine-Needle Aspirates.
VandenBussche CJ; Adams C; Ali SZ; Olson MT
Acta Cytol; 2015; 59(5):377-83. PubMed ID: 26606302
[TBL] [Abstract][Full Text] [Related]
16. Benign call rate and molecular test result distribution of ThyroSeq v3.
Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
[TBL] [Abstract][Full Text] [Related]
17. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
Elliott DD; Pitman MB; Bloom L; Faquin WC
Cancer; 2006 Apr; 108(2):102-9. PubMed ID: 16453320
[TBL] [Abstract][Full Text] [Related]
18. Risk of Malignancy and Risk of Neoplasia in the Bethesda Indeterminate Categories: Study on 4,532 Thyroid Fine-Needle Aspirations from a Single Institution in India.
Mahajan S; Srinivasan R; Rajwanshi A; Radotra B; Panda N; Dey P; Gupta N; Nijhawan R
Acta Cytol; 2017; 61(2):103-110. PubMed ID: 28407624
[TBL] [Abstract][Full Text] [Related]
19. Molecular alterations in Hürthle cell nodules and preoperative cancer risk.
Doerfler WR; Nikitski AV; Morariu EM; Ohori NP; Chiosea SI; Landau MS; Nikiforova MN; Nikiforov YE; Yip L; Manroa P
Endocr Relat Cancer; 2021 Apr; 28(5):301-309. PubMed ID: 33792557
[TBL] [Abstract][Full Text] [Related]
20. Impact of molecular testing on detecting mimics of oncocytic neoplasms in thyroid fine-needle aspirates diagnosed as follicular neoplasm of Hürthle cell (oncocytic) type.
Landau MS; Nikiforov YE; Ohori NP; Chiosea SI
Cancer Cytopathol; 2021 Oct; 129(10):788-797. PubMed ID: 33901345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
